undamentalytics Newsletter
Sign in

Cytokinetics Inc (CYTK) stock

Add to watchlist

Add holding +

NASDAQ: CYTK Nasdaq Biotechnology Next results ~November 4, 2026

D Fundamentals grade

Cytokinetics Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$28

Growth cash-flow model

Base case. Range ~$18–$38. Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Cytokinetics Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Cytokinetics files

Where Cytokinetics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $68m, down 21.1% on a year earlier, against growth of 450.6% a quarter earlier. Free-cash-flow margin fell to -858.2% from -511.7% a year earlier. Operating margin narrowed to -1046.1% from -638.0%. The diluted share count is up 4.9% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 1 of our 4 financial-health checks.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Cytokinetics Inc's trailing-twelve-month revenue fell 21.1% year on year, with a free-cash-flow margin of -858.2%. Where it lags: change in growth rate of -471.7pp ranks 167 of 172 biotechnology companies we cover.

Current signal Balance sheet growing far ahead of sales: Total assets grew 57% year over year while revenue fell 21% — the balance sheet is expanding 78 points faster than the business it supports.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 21.1% over the last 12 months.
  • Growth slowing. The growth rate is 471.7 points lower than a quarter earlier.
  • Loss-making. Operating margin is -1046.1%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 408.2 points on a year ago.
  • Burning cash. Free cash flow was -858.2% of revenue over the last 12 months.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$1.50 against an average estimate of -$1.60: beat by 6.3%
Revenue
$29m, down 57.1% on a year earlier
Share reaction
-2.7% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Guidance given
GAAP combined R&D and SG&A Expense $860m to $890m (full year 2026); non-cash stock-based compensation expense included in GAAP combined R&D and SG&A Expense $130m to $140m (full year 2026)
Next report
November 4, 2026; average EPS estimate -$1.41

Cytokinetics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.5%
  • 1 week+2.1%
  • 1 month-5.4%
  • This year-2.4%
  • 1 year-2.5%
  • 5 years+69.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$67.7M
Operating margin
-1046.1%
Net margin
-1321.1%
EPS (TTM, diluted)
$-7.18

Growth

Revenue growth
−21.1%
Change in growth rate
−471.7 pts
Share count change
+4.9%

Cash

Free cash flow (TTM)
-$581M
FCF margin
-858.2%
Stock pay % of revenue
188.1%

Earnings

Last results
August 6, 2026
Next results (est.)
November 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Announcement
  3. Announcement
  4. Results
  5. Guidance
  6. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Cytokinetics Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Cytokinetics Inc as an operating company, with every model that fits that kind of business. Cost of equity 9.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.95 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$28 ~$18–$38 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: book value or earnings not available
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$11 ~$11–$41 Left out: out of range vs price (0.17x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$28 ~$18–$38 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Cytokinetics Inc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$10.46$12.15$8.15$6.32$10.61$20.78$45.58$45.82$83.49$47.04$63.54$62.03
Market value$406m$517m$403m$344m$611m$1.3bn$3.5bn$4.1bn$8.1bn$5.3bn$7.6bn$7.7bn
+ Net debt (− = net cash)−$50m−$37m−$93m$157000$9m−$37m−$65m$584m$526m$525m$877m$20m
Enterprise value$356m$480m$309m$344m$619m$1.3bn$3.4bn$4.7bn$8.6bn$5.8bn$8.5bn$7.7bn
Multiples
Price / sales 14.2x4.9x30.1x10.9x22.7x24.0x49.8x43.5xn/mn/m86.7x114.1x
Price / earnings —31.4x——————————
Price / free cash flow 94.0x14.6x——————————
EV / EBITDA —24.7x——————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

9 /100

Weak moat

How hard Cytokinetics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -48.0% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -614.3%; its worst year was -16148.4%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 10 years, at a median -526.4% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 76.4% over five years; stock-based pay has been a median 64.3% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (14 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $42m and EPS of −$1.41 (range −$1.65 to −$1.10) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$5.88 +10% $156m +78%
Next −$4.40 +25% $429m +174%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −6.9% on 90 days ago. In the last 30 days, 1 analyst raised Cytokinetics Inc's forecast and 0 cut it.

Consensus EPS forecast Cytokinetics Inc, last 90 days
−$8.00 −$6.00 −$4.00 −$2.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$6.31 Current fiscal year, 60 days ago: −$5.94 Current fiscal year, 30 days ago: −$5.94 Current fiscal year, 7 days ago: −$5.88 Current fiscal year, Now: −$5.88 −$5.88 Next fiscal year, 90 days ago: −$4.69 Next fiscal year, 60 days ago: −$4.45 Next fiscal year, 30 days ago: −$4.45 Next fiscal year, 7 days ago: −$4.41 Next fiscal year, Now: −$4.40 −$4.40

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$6.31−$4.69
60 days ago −$5.94−$4.45
30 days ago −$5.94−$4.45
7 days ago −$5.88−$4.41
Now −$5.88−$4.40

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$1.60 −$1.50 +6.3%
Mar 2026 −$1.65 −$1.67 −1.3%
Dec 2025 −$1.37 −$1.50 −9.7%
Sept 2025 −$1.57 −$1.54 +1.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026
  • GAAP combined R&D and SG&A Expense full year 2026 $860m to $890m GAAP Raised
    “GAAP combined R&D and SG&A Expense $830 million to $870 million $860 million to $890 million” source
  • Non-cash stock-based compensation expense included in GAAP combined R&D and SG&A Expense full year 2026 $130m to $140m GAAP Raised
    “Non-cash stock-based compensation expense included $130 million to $120 million $140 million to $130 million in GAAP combined R&D and SG&A Expense” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

22 analysts, Oct 2026
Buy2091%
Hold29%
Sell00%

Monthly trend

  1. Oct 2026713222
  2. Sep 2026713222
  3. Aug 2026713222
  4. Jul 2026713222

Counts of recommendations published by analysts covering Cytokinetics Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
20.5%
of tradable shares
Days to cover
8.18
at average volume
Short interest, 1 month
+7%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.6%
of shares
Employees
673
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −2.5%

$63.59 on October 31, 2025 to $62.03

ThenNowEffect
Revenue (last 12 months) $86m $68m −21.1%
P/S multiple 88.0x 114.1x +29.6%
Share count 119m 124m −4.6%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +70.8%

$36.32 on November 3, 2023 to $62.03

ThenNowEffect
Revenue (last 12 months) $10m $68m +580.0%
P/S multiple n/m 114.1x −67.1%
Share count 95m 124m −23.8%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CYTK+119%+1%+82%−44%+35%−2%
Industry peers (median)−36%−57%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CYTK58%58%58%25%58%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CYTK−31%−35%−41%−57%−42%−30%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 72% from January 8, 2024 to May 15, 2025. Getting back needed a 262% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$59.19 – $87.26
From 52-week high
−28.9%
vs 50-day average
−7.7%
vs 200-day average
−11.5%
Volatility (1 year)
42%
Beta vs S&P 500
0.73

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±5.7%
After a week
5 up, 7 down
typical move ±10.1%
After a month
5 up, 7 down
typical move ±13.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −2.7% +0.5% −6.8% −7.8%
May 5, 2026 +13.3% +2.2% +13.3% +9.4%
February 24, 2026 −7.9% +1.6% −11.0% −8.6%
November 5, 2025 +1.1% −0.7% +10.6% +10.1%
August 7, 2025 −2.9% +0.7% +10.2% +48.2%
May 6, 2025 −9.9% −0.4% −16.5% −12.5%
February 27, 2025 −1.8% −0.1% −7.7% −7.8%
August 8, 2024 +8.9% +2.8% +11.4% +9.0%
May 8, 2024 −1.9% +0.6% −7.3% −19.1%
February 27, 2024 −7.5% +0.1% −15.9% −9.6%
November 2, 2023 +3.5% +2.8% −5.7% −3.4%
August 3, 2023 +6.8% −0.7% +4.5% +15.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Cytokinetics Inc in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Cytokinetics Inc
$0 $50M $100M $150M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $7.8M Revenue (TTM), FY23 Q4: $7.5M Revenue (TTM), FY24 Q1: $3.8M Revenue (TTM), FY24 Q2: $3.1M Revenue (TTM), FY24 Q3: $3.2M Revenue (TTM), FY24 Q4: $18.5M Revenue (TTM), FY25 Q1: $19.2M Revenue (TTM), FY25 Q2: $85.7M Revenue (TTM), FY25 Q3: $87.2M Revenue (TTM), FY25 Q4: $88M Revenue (TTM), FY26 Q1: $105.8M Revenue (TTM), FY26 Q2: $67.7M $67.7M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $7.8M
FY23 Q4 $7.5M
FY24 Q1 $3.8M
FY24 Q2 $3.1M
FY24 Q3 $3.2M
FY24 Q4 $18.5M
FY25 Q1 $19.2M
FY25 Q2 $85.7M
FY25 Q3 $87.2M
FY25 Q4 $88M
FY26 Q1 $105.8M
FY26 Q2 $67.7M
Revenue growth, TTM YoY Cytokinetics Inc
-1000% 0% 1000% 2000% 3000% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -94.7% Revenue growth, TTM YoY, FY23 Q4: -92.0% Revenue growth, TTM YoY, FY24 Q1: -96.2% Revenue growth, TTM YoY, FY24 Q2: -68.5% Revenue growth, TTM YoY, FY24 Q3: -58.8% Revenue growth, TTM YoY, FY24 Q4: 145.3% Revenue growth, TTM YoY, FY25 Q1: 412.2% Revenue growth, TTM YoY, FY25 Q2: 2635.7% Revenue growth, TTM YoY, FY25 Q3: 2609.3% Revenue growth, TTM YoY, FY25 Q4: 376.6% Revenue growth, TTM YoY, FY26 Q1: 450.6% Revenue growth, TTM YoY, FY26 Q2: -21.1% -21.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -94.7%
FY23 Q4 -92.0%
FY24 Q1 -96.2%
FY24 Q2 -68.5%
FY24 Q3 -58.8%
FY24 Q4 145.3%
FY25 Q1 412.2%
FY25 Q2 2635.7%
FY25 Q3 2609.3%
FY25 Q4 376.6%
FY26 Q1 450.6%
FY26 Q2 -21.1%
Operating margin (TTM) Cytokinetics Inc
-20000% -15000% -10000% -5000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -6344.4% Operating margin (TTM), FY23 Q4: -6589.7% Operating margin (TTM), FY24 Q1: -13272.0% Operating margin (TTM), FY24 Q2: -16148.4% Operating margin (TTM), FY24 Q3: -16297.8% Operating margin (TTM), FY24 Q4: -2902.7% Operating margin (TTM), FY25 Q1: -2943.3% Operating margin (TTM), FY25 Q2: -638.0% Operating margin (TTM), FY25 Q3: -656.9% Operating margin (TTM), FY25 Q4: -695.4% Operating margin (TTM), FY26 Q1: -605.1% Operating margin (TTM), FY26 Q2: -1046.1% -1046.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -6344.4%
FY23 Q4 -6589.7%
FY24 Q1 -13272.0%
FY24 Q2 -16148.4%
FY24 Q3 -16297.8%
FY24 Q4 -2902.7%
FY25 Q1 -2943.3%
FY25 Q2 -638.0%
FY25 Q3 -656.9%
FY25 Q4 -695.4%
FY26 Q1 -605.1%
FY26 Q2 -1046.1%
FCF margin (TTM) Cytokinetics Inc
-15000% -10000% -5000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -5669.0% FCF margin (TTM), FY23 Q4: -5521.2% FCF margin (TTM), FY24 Q1: -11262.5% FCF margin (TTM), FY24 Q2: -12803.9% FCF margin (TTM), FY24 Q3: -12645.2% FCF margin (TTM), FY24 Q4: -2164.1% FCF margin (TTM), FY25 Q1: -2120.8% FCF margin (TTM), FY25 Q2: -511.7% FCF margin (TTM), FY25 Q3: -519.9% FCF margin (TTM), FY25 Q4: -607.5% FCF margin (TTM), FY26 Q1: -518.8% FCF margin (TTM), FY26 Q2: -858.2% -858.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -5669.0%
FY23 Q4 -5521.2%
FY24 Q1 -11262.5%
FY24 Q2 -12803.9%
FY24 Q3 -12645.2%
FY24 Q4 -2164.1%
FY25 Q1 -2120.8%
FY25 Q2 -511.7%
FY25 Q3 -519.9%
FY25 Q4 -607.5%
FY26 Q1 -518.8%
FY26 Q2 -858.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 82 3 4 8 31 47 29 106 13 32 27 56 70 95 8 18 88 68
EBITDA 28 −48 −47 −40 −33 −14 −37 19 −111 −88 −98 −92 −184 −318 −484 −527 −602 −695
Operating income 26 −50 −48 −40 −34 −15 −37 19 −113 −89 −99 −94 −186 −324 −496 −536 −612 −708
Net income 25 −49 −48 −40 −34 −15 −38 16 −128 −106 −122 −127 −215 −389 −526 −590 −785 −894
Diluted EPS $2.52 −$4.62 −$4.32 −$2.30 −$1.24 −$0.41 −$0.97 $0.39 −$2.59 −$1.95 −$2.11 −$1.97 −$2.80 −$4.33 −$5.45 −$5.26 −$6.54 −$7.18
Growth (year on year)
Revenue — −96.8% +55.2% +89.0% +305.5% +53.2% −38.9% +271.3% −87.4% +135.6% −14.7% +107.8% +26.2% +34.3% −92.0% +145.3% +376.6% −21.1%
EBITDA — −269.8% — — — — — — −673.8% — — — — — — — — —
Operating income — −290.2% — — — — — — −706.8% — — — — — — — — —
Net income — −300.8% — — — — — — −876.7% — — — — — — — — —
Diluted EPS — −283.3% — — — — — — −764.1% — — — — — — — — —
Margins
EBITDA margin 34.5% <−999% <−999% −527.4% −109.2% −30.4% −128.5% 18.3% −833.9% −278.3% −363.2% −165.0% −261.3% −336.6% <−999% <−999% −683.9% <−999%
Operating margin 32.0% <−999% <−999% −535.2% −110.6% −31.4% −130.5% 17.6% −848.3% −282.3% −368.0% −168.3% −264.5% −342.8% <−999% <−999% −695.4% <−999%
Net margin 30.1% <−999% <−999% −534.1% −110.0% −31.2% −130.9% 15.5% −955.9% −337.4% −452.9% −228.0% −305.7% −411.2% <−999% <−999% −891.6% <−999%
Free-cash-flow margin 9.6% <−999% <−999% −444.0% −27.0% −97.9% 15.1% 33.3% −782.7% −324.1% −348.1% −3.8% −271.8% −328.6% <−999% <−999% −607.5% −858.2%
Cash flow
Cash from operations 8 −45 −46 −33 −8 −45 5 37 −102 −101 −91 9 −143 −300 −414 −396 −510 −555
Capital spending 1 0 0 0 1 1 1 2 3 1 3 11 49 11 1 4 25 25
Free cash flow 8 −45 −46 −34 −8 −46 4 35 −105 −102 −94 −2 −191 −311 −416 −400 −535 −581
Stock-based pay 5 4 3 4 4 3 5 7 9 10 11 18 27 48 72 98 112 127
Free cash flow after stock pay 3 −49 −49 −37 −12 −49 −0 28 −114 −112 −104 −20 −218 −359 −488 −498 −647 −708
Balance sheet
Cash 26 18 19 15 20 20 65 67 125 42 36 83 113 66 113 95 123 255
Total debt 0 0 0 0 0 0 15 30 32 42 45 46 47 650 639 620 999 276
Net debt (negative = net cash) −26 −17 −19 −15 −20 −20 −50 −37 −93 0 9 −37 −65 584 526 525 877 20
Diluted shares 10m 11m 12m 18m 27m 36m 39m 43m 49m 54m 58m 65m 77m 90m 97m 112m 120m 124m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 4 checks passed · June 30, 2026
What it owns · $1.9bn
Short-term assets $1.2bnLonger-term assets $716m
What it owes, and who funded it · $2.1bn
Short-term liabilities $181mLonger-term liabilities $1.9bnShareholders' equity $-173m
  • Short-term assets cover short-term liabilities $1.2bn of assets due within a year against $181m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.2bn short-term assets against $1.9bn of longer-dated liabilities.
  • More cash than debt $255m of cash against $276m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$555m of operating cash flow against $276m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Cytokinetics Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+4.9%
year over year
R&D spending
586.6%
of revenue
Days sales outstanding
132 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated CYTK RXRX ABCL WVE VRDN CUVL Median
Revenue, last 12 months $68m $68m $66m $71m $71m $64m $56m
Revenue growth, last 12 months −21.1% 56.2% 101.3% 202.3% >999% 5.2% 12.6%
Revenue growth, 3-year average 89.5% 12.9% −23.0% 20.7% 264.4% — 13.7%
Revenue growth, latest quarter −57.1% 258.5% −76.3% 72.9% 278.7% — 10.2%
Gross margin — 29.2% — — 54.5% 82.9% 82.9%
Operating margin <−999% −725.4% −340.3% −320.9% −569.7% 43.4% −189.4%
Operating margin, 3-year average <−999% −995.4% −667.5% −256.4% <−999% — −363.5%
Net margin <−999% −697.1% −248.8% −296.9% −544.1% 36.0% −169.8%
Cash from operations / revenue −820.8% −455.1% −143.5% −291.9% −468.7% 20.1% −168.0%
Free-cash-flow margin −858.2% −458.0% −180.8% −293.8% −471.0% 18.4% −162.4%
Free-cash-flow margin, 3-year average <−999% −664.1% −373.0% −148.0% <−999% — −310.0%
Stock pay / revenue 188.1% 129.4% 77.2% 52.8% 75.4% 2.5% 20.0%
Change in share count 4.9% 32.7% 1.7% 20.2% 42.0% 0.7% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -21.1% 12.6% 124 of 172
Change in growth rate Growth -471.7pp -0.1pp 167 of 172
Operating margin Profitability -1046.1% -189.4% 136 of 175
Net margin Profitability -1321.1% -157.3% 146 of 180
Free-cash-flow margin Cash generation -858.2% -145.4% 139 of 176
Stock pay as % of revenue Cash generation 188.1% 19.2% 153 of 179
Long-term debt as % of assets Balance sheet 12.9% 20.6% 32 of 78
Change in share count Balance sheet 4.9% 7.9% 67 of 156
Days sales outstanding Balance sheet 132 days 75 days 79 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
License and Milestone Revenues $79.4M 90.1% ▲ 429.0%
Collaboration Revenues $8.7M 9.9% ▲ 150.0%

From Cytokinetics Inc's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$13.7B
Institutions reporting
476
Shares held vs prior quarter
▲ 9.7%
Positions opened / closed
86 / 47

Top buyers and sellers, Q2 2026: 318 institutions bought and 149 sold ; the biggest buyer was Blackrock, Inc (+3.5M shares) and the biggest seller FMR LLC (−5.7M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $1.7B 20.1M 12.5% ▲ 21.4%
T. Rowe Price Investment Management, Inc. $1.6B 18.7M 11.7% ▲ 6.8%
Wellington Management Group LLP $591M 6.9M 4.3% ▼ 13.5%
Vanguard Portfolio Management LLC $572M 6.7M 4.2% ▲ 14.9%
State Street Corp $553M 6.5M 4.1% ▲ 13.0%
Vanguard Capital Management LLC $521M 6.1M 3.8% ▲ 11.5%
FMR LLC $429M 5.0M 3.1% ▼ 53.1%
Avoro Capital Advisors LLC $426M 5.0M 3.1% ▲ 50.0%
Bank Of America Corp $395M 4.6M 2.9% ▲ 48.3%
Geode Capital Management, LLC $316M 3.7M 2.3% ▲ 15.5%
RTW Investments, LP $244M 2.9M 1.8% ▲ 5.2%
Polar Capital Holdings PLC $192M 2.3M 1.4% ▲ 35.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cytokinetics Inc's complete shareholder register. Values are as reported by the filers ; 3 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $52M 85 trades by 10 insiders · 91% under pre-set plans
Net ▼ $52M net selling
Insider Date Trade Shares Price Value
Blum Robert I President & CEO November 2, 2026 Sell pre-set plan 7,500 $62.81 $471,075
Malik Fady Ibraham EVP Research & Development October 20, 2026 Sell pre-set plan 3,500 $64.01 $224,035
Blum Robert I President & CEO October 12, 2026 Sell pre-set plan 7,500 $62.88 $471,600
Malik Fady Ibraham EVP Research & Development October 6, 2026 Sell pre-set plan 3,500 $61.38 $214,830
Blum Robert I President & CEO September 28, 2026 Sell pre-set plan 7,500 $65.46 $490,950
Malik Fady Ibraham EVP Research & Development September 22, 2026 Sell pre-set plan 3,500 $68.29 $239,015
Blum Robert I President & CEO September 15, 2026 Sell pre-set plan 97,926 $69.33 $6.8M
Landry Robert E Director September 15, 2026 Sell pre-set plan 1,000 $72.13 $72,130
Blum Robert I President & CEO September 14, 2026 Sell pre-set plan 7,500 $73.44 $550,800
Landry Robert E Director September 11, 2026 Sell pre-set plan 1,000 $74.66 $74,660
Malik Fady Ibraham EVP Research & Development September 8, 2026 Sell pre-set plan 3,500 $75.46 $264,110
Parshall B Lynne Director September 1, 2026 Sell pre-set plan 5,000 $71.48 $357,400

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 5 trades and filings

In the last 12 months, 1 member of Congress disclosed 2 purchases and 0 sales of Cytokinetics Inc shares.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded September 29, 2026, filed October 12, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded June 30, 2026, filed July 2, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded October 9, 2025, filed November 18, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 5, 2026
  • February 24, 2026
  • November 5, 2025
  • August 7, 2025
  • May 6, 2025

Recent SEC filings

Data status

When each part of this page on Cytokinetics Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Cytokinetics Inc in brief

What does Cytokinetics Inc do?
Cytokinetics Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Cytokinetics Inc's stock ticker?
Cytokinetics Inc trades under the ticker CYTK on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Cytokinetics Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Cytokinetics Inc reported revenue of $67.7M, 21.1% lower than a year earlier, according to its SEC filings.
What is Cytokinetics Inc's free cash flow?
Cytokinetics Inc's free-cash-flow margin is -858.2% of revenue over the trailing twelve months, ranking 139 of the 176 biotechnology companies we cover.
Who are Cytokinetics Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., T. Rowe Price Investment Management, Inc. and Wellington Management Group LLP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Cytokinetics Inc's market cap?
On November 2, 2026, Cytokinetics Inc's market capitalisation was about $7.7B and net debt of $20.3M. Market figures come from third-party market data and may be delayed.
Who are Cytokinetics Inc's competitors?
In our Biotechnology peer group, the companies closest to Cytokinetics Inc are Recursion Pharmaceuticals, Inc., Abcellera Biologics Inc., Wave Life Sciences, Inc., Viridian Therapeutics, Inc.\de and Clinuvel Pharmaceuticals Ltd. The side-by-side comparison below sets their revenue, margins and growth against Cytokinetics Inc's.
Are insiders buying or selling Cytokinetics Inc stock?
Over the last 12 months, Cytokinetics Inc's directors and officers reported 0 open-market purchases and 85 sales on Form 4. The insider trading page charts every trade.
When is Cytokinetics Inc's next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Cytokinetics Inc announces its own schedule.